Other · developed by Spyre Therapeutics
SPY002-072 (also known as SPY002 and SPY072) is a drug studied in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07148414 | Phase 2 | Rheumatoid Arthritis | Active not recruiting | SYRE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Axial SpondyloarthritisAxSpAPsA (Psoriatic Arthritis)Psoriatic ArthritisRheumatic DiseasesRheumatic Joint DiseaseRheumatoid ArthritisRheumatologic Disease
See SYRE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SYRE catalysts and pipeline →